Matthew Henn (Seres Therapeutics): ‘Microbiome research will have a large impact on human health’

Staff editor

06.05.2021

Watch our interview with Matthew Henn, Executive Vice President and Chief Scientific Officer of Seres Therapeutics.

Watch our interview with Matthew Henn, Executive Vice President and Chief Scientific Officer of Seres Therapeutics.

Subscribe to MicrobiomePost newsletter

Take full advantage of MicrobiomePost‘s features.

Via Podgora 12/A, 20122, Milan, Italy – VAT: IT05299040963

This communication is only intended for business-to-business and health care professionals.
This communication is not intended for consumers of final consumer goods.
Nothing on this page is meant to be perceived as an approved claim.

Matthew Henn (Seres Therapeutics): ‘Microbiome research will have a large impact on human health’

Latest related content

New tools reveal insights into Bifidobacterium’s role in gut health

The microbiome isn’t a trend. It’s the health OS we’ve been missing

Delayed gut microbiota maturation in cystic fibrosis may contribute to health issues

How exercise boosts gut health, helping prevent chronic diseases

Restoring vaginal health: Jacques Ravel on Live Biotherapeutics with Lactobacillus crispatus

Engineered viruses target gut bacteria to deliver drugs for inflammation and obesity

Latest News